QIAGEN N.V. QGEN
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS1.94
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.09B | $1.98B | $1.97B | $2.14B | $2.25B | $1.87B | $1.53B | $1.50B | $1.42B | $1.34B |
| Cost of revenue | $790.5M | $1.01B | $731.6M | $757.0M | $800.8M | $637.6M | $521.2M | $500.9M | $495.0M | $493.3M |
| Gross profit | $1.30B | $967.4M | $1.23B | $1.38B | $1.45B | $1.23B | $1.01B | $1.00B | $922.6M | $844.7M |
| SG&A | $125.7M | $113.4M | $119.3M | $129.7M | $128.1M | $111.7M | $112.3M | $104.6M | $102.1M | — |
| Total operating expenses | $833.6M | $869.6M | $823.8M | $853.1M | $820.7M | $846.3M | $1.03B | $734.4M | $769.1M | $745.8M |
| Operating income | $465.9M | $97.7M | $409.9M | $531.5M | $630.1M | $386.4M | -$26.1M | $266.6M | $153.4M | $98.8M |
| Interest expense | $33.3M | $43.8M | $53.4M | $58.4M | $54.5M | $71.3M | $74.2M | $67.3M | $49.7M | $39.0M |
| Pre-tax income | $490.3M | $121.1M | $429.8M | $512.6M | $625.8M | $439.5M | -$77.8M | $225.7M | $114.4M | $56.9M |
| Income tax | $65.4M | $37.6M | $88.5M | $89.4M | $113.2M | $80.3M | $36.3M | $35.4M | $74.0M | $23.4M |
| Net income | $424.9M | $83.6M | $341.3M | $423.2M | $512.6M | $359.2M | -$41.5M | $190.4M | $40.4M | $80.4M |
| EPS, basic | 1.96 | 0.38 | 1.50 | 1.86 | 2.25 | 1.57 | -0.18 | 0.84 | 0.18 | 0.34 |
| EPS, diluted | 1.94 | 0.37 | 1.48 | 1.84 | 2.21 | 1.53 | -0.18 | 0.82 | 0.17 | 0.34 |
| Shares, diluted (wtd. avg.) | $218.9M | $224.7M | $230.6M | $230.1M | $232.0M | $234.2M | $226.8M | $233.5M | $233.0M | $239.0M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $839.0M | $663.6M | $668.1M | $730.7M | $880.5M | $598.0M | $629.4M | $1.16B | $657.7M | $439.2M |
| Short-term investments | $259.9M | $489.4M | $389.7M | $687.6M | $184.8M | $117.2M | $129.6M | $234.6M | $359.2M | $93.0M |
| Receivables | $402.6M | $349.3M | $381.9M | $323.8M | $362.1M | $380.5M | $385.1M | $351.6M | $329.1M | $278.2M |
| Inventory | $301.9M | $279.3M | $398.4M | $358.0M | $327.5M | $291.2M | $170.7M | $162.9M | $155.9M | $136.6M |
| Total current assets | $2.00B | $1.96B | $2.15B | $2.39B | $2.11B | $1.62B | $1.57B | $2.16B | $1.65B | $1.04B |
| Property, plant and equipment | $923.9M | $753.6M | $765.0M | $662.2M | $638.2M | $559.4M | $455.2M | $511.7M | $494.3M | $436.7M |
| Goodwill | $2.70B | $2.43B | $2.48B | $2.35B | $2.35B | $2.36B | $2.14B | $2.11B | $2.01B | $1.93B |
| Other intangibles | $386.4M | $303.8M | $526.8M | $544.8M | $627.4M | $726.2M | $632.4M | $475.0M | $499.3M | $557.2M |
| Total assets | $6.28B | $5.69B | $6.12B | $6.29B | $6.15B | $5.87B | $5.24B | $5.75B | $5.04B | $4.31B |
| Accounts payable | $72.7M | $83.3M | $84.2M | $98.7M | $101.2M | $118.2M | $84.8M | $69.4M | $59.2M | $51.2M |
| Short-term debt | $0 | $551.9M | $588.0M | $389.6M | $847.6M | $42.5M | $285.2M | $503.1M | $0 | — |
| Total current liabilities | $512.1M | $1.04B | $1.08B | $974.5M | $1.52B | $572.2M | $951.3M | $972.2M | $324.8M | $308.4M |
| Long-term debt | $1.65B | $839.7M | $921.8M | $1.47B | $1.09B | $1.88B | $1.42B | $1.67B | $1.76B | $1.07B |
| Retained earnings | $2.75B | $2.45B | $2.46B | $2.16B | $1.79B | $1.32B | $1.18B | $1.38B | $1.25B | $1.26B |
| Total equity | $3.78B | $3.57B | $3.81B | $3.47B | $3.10B | $2.80B | $2.54B | $2.63B | $2.54B | $2.61B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $654.3M | $673.6M | $459.5M | $715.3M | $639.0M | $457.8M | $330.8M | $359.5M | $286.8M | $341.6M |
| Depreciation and amortisation | $193.7M | $203.3M | $205.3M | $208.4M | $214.9M | $205.0M | $231.5M | $206.4M | $216.4M | $213.1M |
| Stock-based compensation | $50.4M | $43.6M | $47.1M | $49.5M | $38.4M | $40.9M | $65.9M | $40.1M | $34.4M | $28.3M |
| Capital expenditure | $201.0M | $167.2M | $149.7M | $129.2M | $189.9M | $132.8M | $118.0M | $109.8M | $90.1M | $74.5M |
| Investing cash flow | -$305.3M | -$249.2M | -$87.7M | -$726.8M | -$202.4M | -$443.3M | -$222.3M | -$211.4M | -$464.3M | -$179.1M |
| Financing cash flow | -$179.0M | -$422.9M | -$433.8M | -$125.8M | -$150.4M | -$50.1M | -$639.1M | $360.4M | $387.2M | -$10.6M |
| Dividends paid | $54.2M | $0 | $0 | — | — | — | — | — | — | — |
| Buybacks | $280.1M | $292.1M | $0 | $0 | $100.0M | $64.0M | $74.5M | $104.7M | $61.0M | $0 |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001015820-26-000018.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $187.23B | 22.3x | 2.4% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $45.01B | — | — |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |